menu
    • menu
    [{"orgOrder":0,"company":"Newsoara Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bexagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Newsoara Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Newsoara Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Newsoara Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Newsoara Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bexagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Phase III","graph3":"Newsoara Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Newsoara Biopharma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Newsoara Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"TheracosBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bexagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"TheracosBio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ Undisclosed"},{"orgOrder":0,"company":"TheracosBio","sponsor":"Independent Pharmacy Cooperative","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Bexagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"TheracosBio \/ Independent Pharmacy Cooperative","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ Independent Pharmacy Cooperative"},{"orgOrder":0,"company":"TheracosBio","sponsor":"BAMCO Africa","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Bexagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"TheracosBio \/ BAMCO Africa","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ BAMCO Africa"},{"orgOrder":0,"company":"TheracosBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bexagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"TheracosBio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ Undisclosed"},{"orgOrder":0,"company":"TheracosBio","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bexagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"TheracosBio \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ Undisclosed"},{"orgOrder":0,"company":"TheracosBio","sponsor":"SmithRx","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Collaboration","leadProduct":"Bexagliflozin","moa":"Sodium\/glucose cotransporter 2","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"TheracosBio","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"TheracosBio \/ SmithRx","highestDevelopmentStatusID":"15","companyTruncated":"TheracosBio \/ SmithRx"}]

    Find Clinical Drug Pipeline Developments & Deals for Bexagliflozin

    Menu

    Bexagliflozin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TheracosBio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            TheracosBio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : BAMCO Africa

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            TheracosBio and BAMCO Africa Partner for Affordable Diabetes Medication

                            Details : The partnership aims to bring Brenzavvy (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes, to patients in Sub-Saharan Africa.

                            Product Name : Brenzavvy

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 17, 2024

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : BAMCO Africa

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TheracosBio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            TheracosBio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TheracosBio's BRENZAVVY is Non-Inferior to Dapagliflozin in Chinese T2D Patients

                            Details : Brenzavvy (bexagliflozin) is an FDA-approved oral sodium-glucose cotransporter 2 inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

                            Product Name : Brenzavvy

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 12, 2024

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            TheracosBio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            TheracosBio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Independent Pharmacy Cooperative

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            IPC Secures Exclusive Distribution Rights for BRENZAVVY® with TheracosBio

                            Details : Under the agreement, IPC gains distribution rights for Brenzavvy (bexagliflozin), an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, used for adults with type 2 diabetes mellitus.

                            Product Name : Brenzavvy

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            February 01, 2024

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Independent Pharmacy Cooperative

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TheracosBio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            TheracosBio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : SmithRx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            TheracosBio and SmithRx Collaborate to Offer Newly Approved Diabetes Drug Brenzavvy™ (bexagliflozin) to Memb...

                            Details : Under the collaboration, SmithRx will offer access to Brenzavvy (bexagliflozin), a sodium glucose transporter 2 (SGLT2) inhibitor and TheracosBio’s FDA-approved oral medication for adults with type 2 diabetes.

                            Product Name : Brenzavvy

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 17, 2023

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : SmithRx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TheracosBio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            TheracosBio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TheracosBio Announces Commercial Availability of Brenzavvy (bexagliflozin) for the Treatment of Adults with Ty...

                            Details : Brenzavvy (bexagliflozin), a SGLT2 inhibitor which helps in reducing renal reabsorption of filtered glucose and lowers the renal threshold for glucose, is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diab...

                            Product Name : Brenzavvy

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 13, 2023

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TheracosBio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed

                            TheracosBio

                            U.S.A arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TheracosBio Announces FDA Approval of Brenzavvy™ (bexagliflozin) for the Treatment of Adults with Type 2 Dia...

                            Details : Brenzavvy™ (bexagliflozin) is a SGLT2 inhibitor thus, reducing renal reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.

                            Product Name : Brenzavvy

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 23, 2023

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Newsoara Biopharma

                            Country arrow
                            Luxepack
                            Not Confirmed

                            Newsoara Biopharma

                            Country arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects

                            Details : THR-1442 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 11, 2022

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Newsoara Biopharma

                            Country arrow
                            Luxepack
                            Not Confirmed

                            Newsoara Biopharma

                            Country arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM

                            Details : THR-1442 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 16, 2021

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Theracos

                            Country arrow
                            Luxepack
                            Not Confirmed

                            Theracos

                            Country arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Efficacy of Bexagliflozin in Subjects With Moderate Hepatic Impairment

                            Details : Bexagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 15, 2018

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Theracos

                            Country arrow
                            Luxepack
                            Not Confirmed

                            Theracos

                            Country arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hype...

                            Details : Bexagliflozin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Essential Hypertension.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 02, 2018

                            Lead Product(s) : Bexagliflozin

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth